Merck Dividendes et rachats
Dividende contrôle des critères 4/6
Merck est une société versant des dividendes avec un rendement actuel de 2.36%. La prochaine date de paiement est le 7th October, 2026 avec une date ex-dividende de 15th September, 2026.
Informations clés
2.4%
Rendement du dividende
1.1%
Rendement des rachats
| Rendement total pour l'actionnaire | 3.5% |
| Rendement futur des dividendes | 2.6% |
| Croissance des dividendes | 6.5% |
| Prochaine date de paiement du dividende | 07 Oct 26 |
| Date ex-dividende | 15 Sep 26 |
| Dividende par action | n/a |
| Ratio de distribution | 259% |
Mises à jour récentes sur les dividendes et les rachats
Recent updates
Mise à jour du récit • Sep 09
MRK: Cancer Vaccine Breakthrough And Broader Pipeline Will Shape Post Keytruda Outlook
Merck's analyst fair value estimate has risen from $136.85 to $150.42 as analysts factor in expectations for higher long term revenue growth, slightly better profit margins, and a richer projected future P/E multiple. This revised outlook is supported by a wave of price target increases tied to positive melanoma vaccine data and broader pipeline progress.
Mise à jour du récit • Aug 26
MRK: Cancer Vaccine Breakthrough Will Support Higher Future Oncology Weighted P E Multiple
Merck's analyst fair value estimate has moved from $155 to $186 as analysts factor in stronger revenue growth assumptions, higher projected profit margins, and a modestly higher future P/E multiple following recent updates to its cancer vaccine and oncology pipeline. Analyst Commentary Recent research on Merck highlights a clear divide between bullish analysts who see the cancer vaccine and oncology pipeline as meaningful long term drivers, and more cautious voices focused on valuation and the upcoming Keytruda loss of exclusivity.Seeking Alpha • Aug 20
Merck And Moderna's Melanoma Results
Summary Moderna and Merck have been working together for some years now on cancer therapies that would combine Merck’s Keytruda antibody with personalized mRNA immunotherapy from Moderna. Since each cancer patient’s tumor case is indeed somewhat different from any other, the idea is to use biopsy and blood samples to tailor the therapeutic-vaccine effects of the mRNA injections to each patient's profile of neoantigens being produced by their tumors. The trial met its primary endpoint of improvement in recurrance-free survival and a secondary endpoint of distant metastasis-free survival. This was apparently the first prespecified interim readout; the trial will continue to evaluate endpoints like overall survival. Read the full article on Seeking AlphaMise à jour du récit • Aug 12
MRK: Pipeline Execution And Patent Cliff Response Will Shape Future Earnings Balance
Merck's updated analyst price target framework now points to a fair value of $136.85, up from $132.78. Analysts link this shift to a series of higher Street targets that emphasize the company's dividend profile, pipeline progress, and M&A optionality.
Mise à jour du récit • Jul 29
MRK: Pipeline Execution And Policy Headwinds Will Restrain Multiple Expansion
Merck's updated analyst price target reflects a modest fair value move to about $108, with analysts pointing to refreshed pipeline assumptions, sector re-rating, and multiple expansion as key drivers behind the change. Analyst Commentary Recent commentary on Merck highlights a mix of optimism around the pipeline and sector setup alongside a more cautious tone on execution risks, earnings durability, and regulatory overhangs.Mise à jour du récit • Jul 14
MRK: Oncology Pipeline And Patent Cliff Responses Will Shape Earnings Balance
Merck's updated analyst price target moves higher by a few dollars, reflecting modestly higher fair value estimates to $132.78, alongside generally supportive analyst views around the company's Q2 setup, sector fund flows, and long term pipeline assumptions. Analyst Commentary Analysts covering Merck are broadly constructive ahead of the upcoming Q2 report, with most recent research focused on price target updates, the earnings setup, and how the pipeline and regulatory backdrop could shape the stock's risk and reward profile.Mise à jour du récit • Jun 30
MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple
Analysts have raised the Merck fair value estimate to $155 from $150, pointing to higher long term earnings expectations and multiple expansion, as reflected in recent Street price target increases to as high as $155. Analyst Commentary Recent Street research on Merck reflects a cluster of constructive views, with several bullish analysts lifting price targets and highlighting long term earnings potential.Mise à jour du récit • Jun 15
MRK: Terns Acquisition Execution And Bidding Risk Will Constrain Future Upside
Analysts have nudged their price targets for Merck higher by about $3 to $15 in recent research, supporting a modest increase in the fair value estimate to $101.68. This reflects updated profit margin assumptions and a slightly lower future P/E, along with adjustments to revenue growth expectations and discount rates.Mise à jour du récit • Jun 01
MRK: Oncology Pipeline And Terns Deal Will Shape Future Earnings Balance
Analysts have nudged their average price targets on Merck higher by $3 to $15 in recent weeks, citing updated views on the company’s oncology pipeline, the Terns Pharmaceuticals deal, and specific assets like Sac TMT that some expect could materially influence Merck’s long term earnings profile. Analyst Commentary Recent Street research around Merck clusters around two main themes, the potential of key pipeline assets like Sac TMT and TERN-701, and how recent study outcomes and deal activity could affect execution risk and valuation.
Mise à jour du récit • May 21
Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026
Announcement Overview Analyst: Qudus Adebara (Founder, Wane Investment House) Merck & Co., Inc. (“Merck” or “the Company”), known as MSD outside the United States and Canada, has announced that it will present more than 100 abstracts spanning over 25 cancer types at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , scheduled for May 29 – June 2, 2026.Mise à jour du récit • May 19
Merck Completes Acquisition of Terns Pharmaceuticals
Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.Mise à jour du récit • May 17
MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance
Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.Article d’analyse • May 11
Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...Mise à jour du récit • May 02
MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple
Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.Mise à jour du récit • Apr 19
Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)
Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.Mise à jour du récit • Apr 18
MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple
Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.Mise à jour du récit • Apr 04
MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside
Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.Mise à jour du récit • Mar 21
MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple
The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.Mise à jour du récit • Mar 06
MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside
Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.Mise à jour du récit • Feb 20
MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance
Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.Mise à jour du récit • Feb 06
MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple
Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.Stabilité et croissance des paiements
Récupération des données sur les dividendes
Dividende stable: Les dividendes par action de MRK sont restés stables au cours des 10 dernières années.
Dividende croissant: Les paiements de dividendes de MRK ont augmenté au cours des 10 dernières années.
Rendement des dividendes par rapport au marché
| Merck Rendement des dividendes par rapport au marché |
|---|
| Segment | Rendement du dividende |
|---|---|
| Entreprise (MRK) | 2.4% |
| 25% du marché (US) | 1.4% |
| 25% du marché (US) | 4.1% |
| Moyenne du secteur (Pharmaceuticals) | 1.9% |
| Analyste prévisionnel (MRK) (jusqu'à 3 ans) | 2.6% |
Dividende notable: Le dividende de MRK ( 2.36% ) est supérieur à celui des 25 % des payeurs de dividendes les plus faibles du marché US ( 1.36% ).
Dividende élevé: Le dividende de MRK ( 2.36% ) est faible par rapport aux 25 % des premiers payeurs de dividendes du marché US ( 4.11% ).
Bénéfice distribué aux actionnaires
Couverture des revenus: Avec son ratio de distribution élevé (259.4%), les paiements de dividendes de MRK ne sont pas bien couverts par les bénéfices.
Paiement en espèces aux actionnaires
Couverture des flux de trésorerie: Avec son cash payout ratio raisonnable (52.2%), les paiements de dividendes de MRK sont couverts par les flux de trésorerie.
Découvrir des entreprises qui versent des dividendes élevés
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/09/14 03:42 |
| Cours de l'action en fin de journée | 2026/09/11 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Merck & Co., Inc. est couverte par 49 analystes. 23 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Emily Field | Barclays |